|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication November 27, 2007.
Revised May 19, 2008.
Accepted for publication May 20, 2008.
O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl-adducts from the O6-guanine in DNA, and is a crucial defense against O6-alkylating agent-induced cytotoxicity. We demonstrated here that two camptothecin (CPT)-resistant cell lines (CPT30 and KB100) were more sensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea (BCNU) than their parental cells. Enhanced sensitivity to BCNU in these two CPT-resistant cells involved transcriptional repression of the MGMT gene. The mechanism of MGMT gene down-regulation in CPT-resistant cells was not through gene abnormality, mRNA stability, and CpG island hypermethylation. However, the high level of methyl-CpG-binding protein 2 (MeCP2) and di-methylation of H3K9 in the promoter region were found in CPT30 and KB100 cells. Furthermore, increased MeCP2 binding on MGMT promoter were also found to be corrected with MGMT gene silencing in short-term CPT treatment, thus, enhanced BCNU sensitivity in CPT-treated cells. Taken together, we suggest that CPT is able to suppress the transcription of MGMT gene through recruiting of MeCP2 and H3K9 di-methylation thus cause synergistic interaction with BCNU. These findings provide a possible explanation regarding why the combination of CPT and BCNU results in better objective response than single use alone. In addition, this study also suggest a new indication to treat patients whom refractory CPT derivatives with BCNU.
Key words:
Resistance, Topoisomerases